KKR & Co. completed its $5.89 billion acquisition of Integer Holdings in August, finalizing the largest private equity healthcare transaction in a month where total PE dealmaking contracted sharply. The medical device manufacturer, which specializes in cardiac rhythm management and neuromodulation components, moved off public markets without regulatory friction. No antitrust extension. No financing hiccup. The deal cleared in a quarter when larger buyouts stalled on valuation gaps.

Global private equity activity fell 34% year-over-year in August by transaction count, according to disclosed deal registries. Healthcare represented 41% of completed buyout value despite accounting for 19% of transaction volume, a concentration ratio not seen since the second quarter of 2021 when pandemic-era device demand was still elevated. KKR paid Integer shareholders $107.50 per share in cash, a 22% premium to the 30-day volume-weighted average before deal announcement in April. The exit multiple suggests the firm is underwriting high-single-digit organic growth in implantable components, a segment where reimbursement visibility remains stronger than elective procedure categories.

The Integer close matters because it confirms three allocation trends simultaneously. First, mega-cap PE can still execute $5 billion-plus healthcare takes in a high-rate environment if the asset has contracted revenue and regulatory moats. Integer's customer concentration—47% of revenue from four OEM partners including Medtronic and Boston Scientific—would typically introduce execution risk, but KKR's co-investment from its Health Care Strategic Growth Fund II signals confidence in multi-year supply agreements already locked. Second, the deal demonstrates that private equity's August slowdown was driven by sponsor hesitation on cyclical industrials and consumer discretionary, not a systemic financing freeze. Healthcare debt markets remained open; Integer's acquisition financing included a $2.1 billion term loan that priced at SOFR plus 375 basis points, tighter than comparable software LBOs by 50-75 basis points. Third, this accelerates the shift toward assets with embedded operating leverage rather than multiple arbitrage. Integer's EBITDA margins expanded 340 basis points over the prior eighteen months before acquisition, driven by manufacturing footprint consolidation that KKR can extend across its medical device portfolio.

Operators and allocators should monitor whether KKR begins bolt-on acquisitions within Integer's neuromodulation segment in the next six to nine months, particularly targeting smaller component suppliers with exposure to spinal cord stimulation or deep brain stimulation platforms where reimbursement expansion is outpacing cardiac categories. Watch for refinancing activity in Q1 2025 if SOFR forwards decline as expected; KKR historically reprices term loans within twelve months of close when rate curves shift favorably. Family offices with exposure to medical technology secondaries should note that Integer's take-private removes a visible comparable for valuation, tightening the public reference set for mid-cap device manufacturers and likely compressing illiquidity discounts by 100-150 basis points in private marks.

The August PE landscape now has one fewer exit candidates and one more proof point that healthcare can absorb large checks when growth is contracted and margins are ascending. KKR's next comparable sale will likely set the private-market clearing price for cardiac component platforms through 2026.